Using organotypic tumor slices, they tested the effect of CXCR4, and the PD-1 blockade, either alone or in combination, by treatment with AMD3100, a small molecule that inhibits CXCR4 and a PD-1 blocking monoclonal antibody, a strategy previously described [40]. The gene discussed is CXCR4; the disease is neoplasm.